Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.

abstract：:The purpose of this paper is to report the clinical characteristics and treatment outcome following different therapeutic approaches in a large series of patients with primary low-grade MALT lymphoma of the stomach. A total of ninety-three patients (median age 63 years) were reviewed. The patients were treated by diff...

journal_title：Leukemia & lymphoma

authors： Pinotti G,Zucca E,Roggero E,Pascarella A,Bertoni F,Savio A,Savio E,Capella C,Pedrinis E,Saletti P,Morandi E,Santandrea G,Cavalli F

更新日期：1997-08-01 00:00:00

abstract：:The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. In this retrospective study, we used the methylation-sp...

journal_title：Leukemia & lymphoma

authors： Lee GW,Kang JH,Kim IS,Kim HG,Ko GH,Lee JH,Kim DC,Song DH,Yang JW,Lee JS

更新日期：2009-12-01 00:00:00

abstract：:Multiple myeloma represents a B cell malignancy characterized by a monoclonal proliferation of plasma cells. A striking feature of the disease is the tendency of the malignant plasma cells to affect mainly the bone marrow environment and to invade the peripheral blood only in the terminal stage. The growth of myeloma ...

journal_title：Leukemia & lymphoma

authors： Van Riet I,Van Camp B

更新日期：1993-04-01 00:00:00

abstract：:CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

journal_title：Leukemia & lymphoma

authors： Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

更新日期：2019-12-01 00:00:00

abstract：:Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between i...

journal_title：Leukemia & lymphoma

authors： Wong-Sefidan I,Byrtek M,Zhou X,Friedberg JW,Flowers CR,Zelenetz AD,Dawson KL,Reid E

更新日期：2017-04-01 00:00:00

abstract：:The Italian Registry for hairy cell leukemia (HCL) has recorded 725 patients with HCL diagnosed over 25 years. We analysed this large series of patients with the aim of providing an evaluation of changes in clinical presentation, impact of initial therapy and modifications in prognostic factors over the period of two ...

journal_title：Leukemia & lymphoma

authors： Frassoldati A,Lamparelli T,Federico M,Annino L,Capnist G,Pagnucco G,Dini E,Resegotti L,Damasio EE,Silingardi V

更新日期：1994-04-01 00:00:00

abstract：:Loss of cylindromatosis gene (CYLD) expression has been observed in various cancers, including chronic lymphocytic leukemia (CLL). As a deubiquitination enzyme, CYLD regulates the proliferation, development and activation of lymphoid cells. Here we determined the CYLD mRNA expression by quantitative polymerase chain r...

journal_title：Leukemia & lymphoma

authors： Wu W,Zhu H,Fu Y,Shen W,Xu J,Miao K,Hong M,Xu W,Liu P,Li J

更新日期：2014-03-01 00:00:00

abstract：:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

journal_title：Leukemia & lymphoma

authors： Dhodapkar MV,Sanderson RD

更新日期：1999-06-01 00:00:00

abstract：:Previous studies on the association of Thymidylate synthase (TYMS) polymorphisms with risk of hematological malignancies have produced conflicting results. The purpose of this meta-analysis was to define the effect of TYMS 5'-untranslated enhanced region (TSER) and 3'-untranslated region (TS3'-UTR) polymorphisms on th...

journal_title：Leukemia & lymphoma

authors： Weng Y,Zhang J,Tang X,Xie X,Chen G

更新日期：2012-07-01 00:00:00

abstract：:Interleukin-1 receptor type 1 (IL-1R), IL-2 receptor alpha subunit (IL-2R) and IL-6 receptor alpha subunit (IL-6R) mRNA expression in peripheral blood mononuclear cells (PBMC) in 17 patients who underwent allogeneic bone marrow transplantation (allo BMT) and 2 patients who underwent autologous transplantation were ana...

journal_title：Leukemia & lymphoma

authors： Tanaka J,Imamura M,Kasai M,Zhu X,Kobayashi S,Hashino S,Higa T,Sakurada K,Asaka M

更新日期：1995-10-01 00:00:00

abstract：:Analysis of different ribonucleotide reductase inhibitors to modulate arabinosylcytosine (ara-C) metabolism suggested that pretreatment with arabinosyl-2-fluoroadenine (F-ara-A) significantly potentiated the rate of ara-CTP (5'-triphosphate of ara-C) accumulation in both quiescent lymphocytes (p = 0.046) and in cyclin...

journal_title：Leukemia & lymphoma

authors： Gandhi V,Estey E,Keating MJ,Plunkett W

更新日期：1993-01-01 00:00:00

abstract：:The interaction between neoplastic as well as normal T cells and vascular endothelial cells which is mediated by adhesion molecules play a key role in their trafficking, localization and infiltration. This brief article reviews our studies on the expression of adhesion molecules on leukemic cells isolated from patient...

journal_title：Leukemia & lymphoma

authors： Uchiyama T,Ishikawa T,Imura A

更新日期：1995-02-01 00:00:00

abstract：:Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

journal_title：Leukemia & lymphoma

authors： Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

更新日期：2002-05-01 00:00:00

abstract：:To identify epigenetically silenced miRNAs and to investigate their influences on predictive target oncogenes in extranodal natural killer/T-cell lymphoma (NKTCL). Decitabine treatment was performed to evaluate methylated miRNAs in NKTCL cells. The relationship between a given miRNA and its target mRNA was validated u...

journal_title：Leukemia & lymphoma

authors： Go H,Jang JY,Kim CW,Huh J,Kim PJ,Jeon YK

更新日期：2020-01-01 00:00:00

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:In this report a rare case of spontaneous regression of a long-standing chemotherapy resistant low grade non-Hodgkin's lymphoma (NHL) of follicular small cleaved cell type is described. Extensive bulky lymphadenopathy substantially resolved, 7 months before the diagnosis of acute myelomonocytic leukaemia was establish...

journal_title：Leukemia & lymphoma

authors： Grigg AP,Gascoyne RD,Barnett MJ

更新日期：1996-01-01 00:00:00

abstract：:Indolent lymphomas primarily involving the skeleton (iPBL) represent < 1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgk...

journal_title：Leukemia & lymphoma

authors： Govi S,Christie D,Mappa S,Marturano E,Bruno-Ventre M,Messina C,Medina EA,Porter D,Radford J,Heo DS,Park Y,Pro B,Jayamohan J,Pavlakis N,Zucca E,Gospodarowicz M,Ferreri AJ,International Extranodal Lymphoma Study Group.

更新日期：2014-08-01 00:00:00

abstract：:DNA methylation (DNAm) silences gene expression and may play a role in immune dysregulation that is characteristic of adolescent/young adult Hodgkin lymphoma (AYAHL). We used the Infinium HumanMethylation27 BeadChip to quantify DNAm in blood (N = 9 pairs, mean age 57.4 y) or saliva (N = 36 pairs, mean age 50.0 y) from...

journal_title：Leukemia & lymphoma

authors： Wang J,Van Den Berg D,Hwang AE,Weisenberger D,Triche T,Nathwani BN,Conti DV,Siegmund K,Mack TM,Horvath S,Cozen W

更新日期：2019-06-01 00:00:00

abstract：:The management of lymphoma in patients with primary immunodeficiency (PID) is challenging because of its poor prognosis and complex therapeutic approaches. We conducted a systematic literature review of case-reports, case-series, and cohorts indexed in MEDLINE reporting the association of lymphoma and PID. One hundred...

journal_title：Leukemia & lymphoma

authors： Herber M,Mertz P,Dieudonné Y,Guffroy B,Jung S,Gies V,Korganow AS,Guffroy A

更新日期：2020-02-01 00:00:00

abstract：:The (1;19)(q23;p13) translocation, leading to the production of the E2A/PBX1 fusion transcript, is one of the most common translocations in pediatric B-lineage acute lymphoblastic leukemia (ALL). It was assumed to be associated with a poor clinical outcome, although intensive therapy and bone marrow transplantation ha...

journal_title：Leukemia & lymphoma

authors： Piccaluga PP,Malagola M,Rondoni M,Ottaviani E,Testoni N,Laterza C,Visani G,Pileri SA,Martinelli G,Baccarani M

更新日期：2006-03-01 00:00:00

abstract：:The NK-like family of homeobox genes includes TLX1, TLX3 and NKX2-5, which are ectopically activated in distinct subsets of T-cell acute lymphoblastic leukemia (T-ALL) cells. Here we analysed their effect on the miR-17-92 cluster overexpressed in several types of cancer, including T-ALL. The pri-miR-17-92 polycistron ...

journal_title：Leukemia & lymphoma

authors： Nagel S,Venturini L,Przybylski GK,Grabarczyk P,Schmidt CA,Meyer C,Drexler HG,Macleod RA,Scherr M

更新日期：2009-01-01 00:00:00

abstract：:The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

journal_title：Leukemia & lymphoma

authors： Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

更新日期：2016-09-01 00:00:00

abstract：:We report two cases of acute nonlymphocytic leukemia (ANLL) in which the circulating leukemic cells showed trisomy of chromosome 4 as the sole cytogenetic abnormality. Trisomy 4 is rarely found in hematopoietic neoplasia and until now the few reported patients had ANLL or myelodysplastic syndrome (MDS). In these two A...

journal_title：Leukemia & lymphoma

authors： Tauchi T,Ohyashiki K,Kodama A,Iwabuchi A,Ohyashiki JH,Toyama K

更新日期：1990-01-01 00:00:00

abstract：:We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

journal_title：Leukemia & lymphoma

authors： Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

更新日期：2007-10-01 00:00:00

abstract：:Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

journal_title：Leukemia & lymphoma

authors： Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

更新日期：2017-06-01 00:00:00

abstract：:We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...

journal_title：Leukemia & lymphoma

authors： Hon C,Chan RT,Ma ES,Shek TW,Yau K,Au WY

更新日期：2006-01-01 00:00:00

abstract：:Data from the large, prospective, multinational, phase 3b JUMP study were analyzed to identify factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Factors associated with higher spleen response rates included International Prognostic Scoring System (IPSS) low/intermediat...

journal_title：Leukemia & lymphoma

authors： Gupta V,Griesshammer M,Martino B,Foltz L,Tavares R,Al-Ali HK,Giraldo P,Guglielmelli P,Lomaia E,Bouard C,Paley C,Tiwari R,Zor E,Raanani P

更新日期：2020-11-19 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

journal_title：Leukemia & lymphoma

authors： Piggin A,Bayly E,Tam CS

更新日期：2017-06-01 00:00:00

abstract：:The prognostic significance of immunophenotype and other features including sex, age, anaemia, WBC, FAB type, and PAS staining were analysed in a group of 389 children newly diagnosed as acute lymphoblastic leukemia (ALL) and treated according to the BFM 1981/1983 protocol. The CR rate was higher (82-94%) in immunophe...

journal_title：Leukemia & lymphoma

authors： Holowiecki J,Koehler M,Zintl Z,Kardos G,Lutz D,Krzemien S,Rewesz T,Brugiatelli M,Callea V,Kachel L

更新日期：1992-06-01 00:00:00